Invitae Oct 4, 2022 Nonprofit's Efforts With Payors to Assess NGS Labs' Variant Interpretations Spark Debate Premium Oct 3, 2022 Highmark Asks Labs for Additional Validation Data on Cancer NGS Tests; Will Other Insurers Follow? Premium Sep 22, 2022 Universal Genetic Testing in Breast Cancer Further Supported in New Invitae-Led Study Aug 18, 2022 Cancer Centers Nudge Oncologists Toward DPYD Testing as PGx Supporters Push For Guidelines Change Premium Aug 17, 2022 Oncologists Consider Germline Testing in Lung Cancer Patients Amid New Data Showing High Prevalence Premium Jun 7, 2022 African American Prostate Cancer Patients Get More VUS, Fewer Actionable Results, Studies Show May 3, 2022 Allelica, Invitae Partner to Build Ancestry-Informed Polygenic Risk Score for Breast Cancer Feb 18, 2022 Invitae Launches Study to Generate Real-World Data on Personalized MRD Test Across Tumor Types Premium Feb 16, 2022 Invitae Garners CE-IVD Mark for Two Comprehensive Genomic Profiling Tests Jan 12, 2022 Invitae Launches Ciitizen Genome Information Management Platform at JPM Nov 9, 2021 Invitae Unveils Plans to Expand Cancer Testing Portfolio Premium Oct 18, 2021 Outcomes4Me Incorporates NCCN Hereditary Cancer Risk Testing Guidelines Into Patient-Facing App Oct 8, 2021 Invitae, Outcomes4Me Collaborate to Improve Breast Cancer Genetic Testing Access Apr 23, 2021 In Brief This Week: AstraZeneca, Amgen, Oncocyte, Rain Therapeutics Apr 5, 2021 Invitae Acquiring Genosity for $200M; Investment Group Provides Firm $1.15B in Senior Notes Feb 26, 2021 In Brief This Week: Kura Oncology, Innovent Biologics, Iaso Biotherapeutics, Invitae, Hologic Jan 14, 2021 Invitae, Pharma Firms Partner to Develop Standard MRD Panel for AML Clinical Trials Jan 13, 2021 JP Morgan Healthcare, Day 2: Eli Lilly, Pfizer, GlaxoSmithKline, Clovis Oncology, Invitae, and More Nov 23, 2020 FDA Accepts Invitae Premarket Approval Submission for Stratafide Companion Diagnostic Nov 17, 2020 Reinsurer SCOR Offering Cancer Genomic Testing as Benefit for Policyholders, Life Insurance Clients Premium Load More Breaking News Flare Therapeutics Raises $123M in Oversubscribed Series B Funding Round William Blair Initiates Coverage of MDxHealth With Outperform Rating White House Report Outlines Goals to Advance Genomic Research, Precision Therapy Development In Brief This Week: Fore Biotherapeutics, RayzeBio, Gilead Sciences, Atossa Therapeutics Bayer to Assess Nubeqa in High-Risk, Early-Stage Hormone-Sensitive Prostate Cancer BridgeBio Begins Phase I/II Study of SHP2 Inhibitor, Opdivo in KRAS-Mutant Solid Tumors
